SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-033507
Filing Date
2023-04-28
Accepted
2023-04-28 08:10:36
Documents
13
Period of Report
2023-04-28
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea177564-8k_protara.htm   iXBRL 8-K 27508
2 PRESS RELEASE DATED APRIL 28, 2023, ISSUED BY THE REGISTRANT ea177564ex99-1_protara.htm EX-99.1 20387
  Complete submission text file 0001213900-23-033507.txt   228151

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE tara-20230428_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tara-20230428_pre.xml EX-101.PRE 22361
5 XBRL SCHEMA FILE tara-20230428.xsd EX-101.SCH 2962
7 EXTRACTED XBRL INSTANCE DOCUMENT ea177564-8k_protara_htm.xml XML 3611
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 23860352
SIC: 2836 Biological Products, (No Diagnostic Substances)